User talk:Yo246yo246/Evaluate an Article

Background Information about UTI
Recurrent urinary tract infections (UTIs) are common in women, causing significant physical and emotional distress. Many believe they can be easily treated with antibiotics, but for those who experience frequent UTIs, the impact on their quality of life is substantial. Long-term antibiotic use not only poses health risks but also contributes to the growing problem of antibiotic resistance, making effective treatment more challenging. Yo246yo246 (talk) 19:45, 6 May 2024 (UTC)

Vaccine Solution: MV140
Therefore, an efficient solution is still on the search but there has been a potential candidate. There are studies being made on creating a UTI vaccine with MV140, also known as Uromune®. It is a vaccine made from heat-inactivated bacteria mixed with in glycerol, sodium chloride, artificial pineapple flavoring, and water (Nickel 2023). It contains specific strains of four types of bacteria: Escherichia coli, Klebsiella pneumoniae, Enterococcus faecalis, and Proteus vulgaris.

This vaccine is taken by spraying it under the tongue twice a day for three months. It's designed to prevent recurrent urinary tract infections (UTIs) and is currently being tested in clinical trials. Studies suggest that MV140 works by stimulating the immune system to produce antibodies and activate certain immune cells, which help protect against UTIs. Yo246yo246 (talk) 19:46, 6 May 2024 (UTC)

Studies
In a conducted study, it involving 89 individuals with a history of urinary tract infections (UTIs), participants were instructed to use two sprays of the vaccine daily for three months. Preliminary results presented at the European Association of Urology Congress in Paris revealed that nine years later, 54 percent of the participants remained free from UTIs. Women in the study remained UTI-free for approximately 4.5 years on average, while men experienced around 3.5 years without UTIs (Rapaport 2024). Dr. Bob Yang, who co-led the study and serves as a consultant urologist at the Royal Berkshire NHS Foundation Trust in the United Kingdom, noted that before receiving the vaccine, all participants had struggled with recurrent UTIs, which can be challenging to treat. Yo246yo246 (talk) 19:49, 6 May 2024 (UTC)

Not Available in the US
Yang expressed optimism about the potential impact of the vaccine on UTI prevention, suggesting that its widespread availability could significantly decrease reliance on antibiotic treatments. However, patients in the United States may face a considerable delay as the vaccine remains in the experimental stage and has not yet received approval from the U.S. Food and Drug Administration (FDA). Therefore, we need to wait for this new vaccine to come and save us. Yo246yo246 (talk) 19:50, 6 May 2024 (UTC)